Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 7/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GALR3 | O60755 | 2/20 | 0.58 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446137 | 0.90 | LMNA (0.69) | PKMTNFLMNAHTTTSHR | |
| SCHEMBL1022300 | 0.89 | TLR8 (0.69) | PKMTNFLMNAHTTTSHR | |
| SCHEMBL31066875 | 0.86 | TLR8 (0.70) | PKMLMNAHTTSMN1; SMN2TP53 | |
| SCHEMBL2943250 | 0.86 | TLR8 (0.70) | PKMLMNAHTTSMN1; SMN2TP53 | |
| SCHEMBL31066882 | 0.86 | TLR8 (0.70) | PKMLMNAHTTSMN1; SMN2TP53 | |
| SCHEMBL17053182 | 0.86 | TLR8 (0.70) | PKMLMNAHTTSMN1; SMN2TP53 | |
| SCHEMBL20242949 | 0.86 | TLR8 (0.70) | PKMLMNAHTTSMN1; SMN2TP53 | |
| SCHEMBL9274775 | 0.86 | TLR8 (0.70) | PKMLMNAHTTSMN1; SMN2TP53 | |
| SCHEMBL2330274 | 0.85 | LMNA (0.69) | PKMTNFLMNAHTTTSHR | |
| Hydrochloric Acid SCHEMBL8158771 | 0.85 | TLR8 (0.68) | PKMLMNAHTTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107422-A1 | 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| EP-3752498-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| EP-3666778-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| WO-2018139876-A1 | NOVEL [1,2,4]TRIAZOLO[4, 3-A]QUINOXALINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BET PROTEIN-RELATED DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | 동화약품주식회사 | 2018-08-02 | — | — | WO | disclosed |
| US-20170244044-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170244044-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20150364692-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| US-7538931-B2 | Ligand exchange thermochromic systems containing exchange metals | PLEOTINT, L.L.C. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7525717-B2 | reversible; laminated; transition metal ion coordinated with a high epsilon ligand and a low epsilon ligand; polymer; separator; variable light transmission windows; polyvinyl butyral; nickel or cobalt iodide ligands; diol, triol or polyol ligands | PLEOTINT, L.L.C. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2040666-A2 | BENZIMIDAZOLES AS COOLING COMPOUNDS | Givaudan SA (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| US-20080106781-A1 | LIGAND EXCHANGE THERMOCHROMIC SYSTEMS CONTAINING EXCHANGE METALS | PLEOTINT, LLC (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080105851-A1 | Exhibiting a reversible change in absorbance of electromagnetic radiation as the temperature of the system is reversibly changed; comprising a transition metal ion and a ligand | PLEOTINT, LLC (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080100902-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080100903-A1 | MULTI-LAYER LIGAND EXCHANGE THERMOCHROMIC SYSTEMS | PLEOTINT, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008028128-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT, L.L.C. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008006236-A2 | BENZIMIDAZOLES AS COOLING COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | PTGER2, PTGES2, PTGER1 | POLB 2944/4885PKM 1896/4885TNF 302/4885 |
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | POLB 4214/4885PKM 4686/4885TNF 3550/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | POLB 2305/4885PKM 3932/4885TNF 2649/4885 |
| US-20150364692-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | LEF1, EZH1, EPCAM | POLB 2400/4885PKM 1899/4885TNF 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.